BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11365379)

  • 1. Strategies for protease inhibitor failure.
    Proj Inf Perspect; 1997 Nov; (23):4-5. PubMed ID: 11365379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virologic failure and salvage therapy.
    HIV Hotline; 1998 Mar; 8(1):2-3. PubMed ID: 11365357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue me.
    Simmons P
    Res Initiat Treat Action; 1998 Aug; 4(5):10. PubMed ID: 11365705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trials for protease failure.
    Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard treatments for HIV, Spring 1997.
    Smith D
    AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Salvage therapy for HIV infection].
    Salzberger B
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():32-7. PubMed ID: 16385870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV treatment options.
    Smith D
    AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term strategies: should some patients wait to start protease inhibitors? Interview with Keith Henry, M.D. Interview by John S. James.
    Henry K
    AIDS Treat News; 1997 Oct; (No 281):1, 3-6. PubMed ID: 11364791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidance offered in drug combination choices.
    AIDS Alert; 1997 Dec; 12(12):135-7. PubMed ID: 11364831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease inhibitors at a glance...
    Notes Undergr; 1998-1999 Winter; (No 38):suppl 1-4. PubMed ID: 11366198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
    Negredo E; Paredes R; Bonjoch A; Tuldrà A; Fumaz CR; Gel S; Garcés B; Johnston S; Arnó A; Balagué M; Jou A; Tural C; Sirera G; Romeu J; Cruz L; Francia E; Domingo P; Arrizabalaga J; Ruiz I; Arribas JR; Ruiz L; Clotet B
    Antivir Ther; 1999; 4 Suppl 3():23-8. PubMed ID: 16021868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Half-full or half-empty: no simple answer on protease inhibitor failure.
    Torres G
    GMHC Treat Issues; 1997 Oct; 11(10):1-2. PubMed ID: 11364818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage therapy.
    Gulick RM
    AIDS Clin Care; 1999 Sep; 11(9):71-3, 77-8. PubMed ID: 11366502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.